JP2022553292A - 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 - Google Patents

操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 Download PDF

Info

Publication number
JP2022553292A
JP2022553292A JP2022523383A JP2022523383A JP2022553292A JP 2022553292 A JP2022553292 A JP 2022553292A JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022553292 A JP2022553292 A JP 2022553292A
Authority
JP
Japan
Prior art keywords
cells
binding domain
cell
fragment
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553292A5 (enExample
Inventor
マトセヴィック，サンドロ
ワン，ジャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2022553292A publication Critical patent/JP2022553292A/ja
Publication of JP2022553292A5 publication Critical patent/JP2022553292A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2022523383A 2019-10-21 2020-10-21 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 Pending JP2022553292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923644P 2019-10-21 2019-10-21
US62/923,644 2019-10-21
PCT/US2020/056723 WO2021081133A1 (en) 2019-10-21 2020-10-21 Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques

Publications (2)

Publication Number Publication Date
JP2022553292A true JP2022553292A (ja) 2022-12-22
JP2022553292A5 JP2022553292A5 (enExample) 2024-01-04

Family

ID=75620220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523383A Pending JP2022553292A (ja) 2019-10-21 2020-10-21 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法

Country Status (6)

Country Link
US (1) US20220362299A1 (enExample)
EP (1) EP4048292A4 (enExample)
JP (1) JP2022553292A (enExample)
AU (1) AU2020371628A1 (enExample)
CA (1) CA3155246A1 (enExample)
WO (1) WO2021081133A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN113621073A (zh) * 2021-07-14 2021-11-09 上海易慕峰生物科技有限公司 一种新型嵌合受体组合物、重组载体、细胞及其应用
CN120459135B (zh) * 2025-07-16 2025-10-10 深圳市中佳生物医疗科技有限公司 Cd73+nk细胞在制备预防或治疗帕金森的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SG11201505858VA (en) * 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
WO2018118494A2 (en) * 2016-12-22 2018-06-28 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
AU2018269194B2 (en) * 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDUARDO BRICENO ET AL., NEUROSURGICAL FOCUS, vol. 14, JPN6024043944, 2003, pages 1 - 6, ISSN: 0005636485 *
JIAO WANG ET AL., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 6:136, JPN6024043945, 2018, pages 1 - 14, ISSN: 0005636484 *
JIAO WANG ET AL.: "Targeting Autophagy Enhances the Adoptive Immunotherapy of Glioblastoma with Multi-Functional Geneti", MOLECULAR THERAPY, vol. Vol. 27, No.4, S1, JPN6024043946, April 2019 (2019-04-01), pages 457 - 458, ISSN: 0005781074 *

Also Published As

Publication number Publication date
CA3155246A1 (en) 2021-04-29
WO2021081133A1 (en) 2021-04-29
EP4048292A1 (en) 2022-08-31
EP4048292A4 (en) 2024-06-19
AU2020371628A1 (en) 2022-05-19
US20220362299A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US12559562B2 (en) Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
ES3009008T3 (en) Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
AU2014236098B8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US20210213063A1 (en) Combination therapy with chimeric antigen receptor (car) therapies
US9573988B2 (en) Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US20220362299A1 (en) Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibiton techniques
JP2021119197A (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP7453971B2 (ja) Ｎｋエンゲージャー分子およびその使用方法
WO2021207290A1 (en) Engineered immune cells
US20220251217A1 (en) Immunotherapy targeting cell surface marker cd72 for the treatment of b-cell malignancies
KR20220101128A (ko) Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법
US20230374454A1 (en) Human immune cells genomically modified to express orthogonal receptors
KR20230110737A (ko) Cd19를 표적화하는 유전자 조작된 t 세포를 사용한 b 세포 악성종양의 동종 세포 요법
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
WO2023159136A9 (en) Epitope engineering of cell-surface receptors
JP2023537104A (ja) シグレック６結合ポリペプチド
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
US20220193138A1 (en) Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
HK40119904A (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)
HK40012714A (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
HK40012714B (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
HK1217498B (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
BR122020024818B1 (pt) Molécula de ácido nucleico isolada, molécula polipeptídica isolada, molécula de car isolada, domínio de ligação anti-egfrviii, vetor, método para produção de uma célula e para gerar uma população de células modificadas por rna, e uso de uma quantidade eficaz de uma célula que expressa uma molécula de car
HK1218922B (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260527